Current Management of In-Stent Restenosis
Journal of Clinical Medicine · 19.04.2024 · 13 (8) · 2377
DOI: 10.3390/jcm13082377 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.04.2024. Verfasst von Daniele Giacoppo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco", Department of Surgery and Medical-Surgical Specialties, U…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco", Department of Surgery and Medical-Surgical Specialties, University of Catania, via Santa Sofia 78, 95124 Catania, Italy.
Zitieren
APA
Giacoppo, D., Mazzone, P. M., & Capodanno, D. (2024). Current Management of In-Stent Restenosis. Journal of Clinical Medicine, 13(8), 2377. https://doi.org/10.3390/jcm13082377
Vancouver
Giacoppo D, Mazzone PM, Capodanno D. Current Management of In-Stent Restenosis. Journal of Clinical Medicine. 2024;13(8):2377. doi:10.3390/jcm13082377
BibTeX
@article{Giacoppo2024,
author = {Giacoppo, Daniele and Mazzone, Placido Maria and Capodanno, Davide},
title = {Current Management of In-Stent Restenosis},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {8},
pages = {2377},
doi = {10.3390/jcm13082377}
}
EUVIMED